.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,692,763

« Back to Dashboard

Claims for Patent: 6,692,763

Title: Methods for treating postmenopausal women using ultra-low doses of estrogen
Abstract:The present invention provides methods for treating physical conditions resulting from postmenopausel estrogen decline in a postmenopausel subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit for carrying out the methods of the present invention.
Inventor(s): Cummings; Steven R. (Mill Valley, CA), Ettinger; Bruce (San Francisco, CA), Ellman; Herman (Mountain Lakes, NJ)
Assignee: The Regents of the University of California (Oakland, CA) Kaiser Foundation Health Plan, Inc. (Oakland, CA) The Permanente Medical Group, Inc. (Oakland, CA) Berlex Laboratories, Inc. (Richmond, CA)
Application Number:09/554,789
Patent Claims: 1. A method for treating a physical condition resulting from estrogen decline in a postmenopausal subject, said method comprising administering to said subject an amount of estrogen which is effective to produce a resulting serum level of said estrogen in said subject that is equivalent to a serum estadiol level not exceeding of between about 5 pg/ml and about 15 pg/ml, wherein: the estrogen is administered orally, parenterally, or transdermally; said physical condition is selected from the group consisting of osteoporosis, headaches, nausea, depression, hot flashes, decrease in bone mineral density, and increased risk or incidence of bone fracture; and the resulting serum level of the estrogen is responsive to the administering of the estrogen.

2. The method of claim 1, wherein said physical condition is selected from the group consisting of postmenopausal estrogen decline, increased risk of osteoporotic bone fracture due to postmenopausal osteoporosis, and loss of bone mineral density.

3. The method of claim 1, wherein said amount of estrogen which is administered is effective to produce a serum level of said estrogen equivalent to a serum estradiol level in said subject of between about 5 pg/ml and about 10 pg/ml.

4. The method of claim 1, wherein said estrogen is estradiol.

5. The method of claim 4, comprising orally administering said amount of estrogen.

6. The method of claim 5, wherein said amount of estrogen administered is less than 0.5 mg/day.

7. The method of claim 5, wherein said amount of estrogen administered is between 0.1-0.25 mg/day.

8. The method of claim 4, comprising parenterally administering said amount of estrogen.

9. The method of claim 8, wherein said amount of estrogen administered is less than about 20 .mu.g/day.

10. The method of claim 8, wherein said amount of estrogen administered is between 5-15 .mu.g/day.

11. The method of claim 8, wherein said amount of estrogen administered is about 10 .mu.g/day.

12. The method of claim 4, comprising transdermally administering said amount of estrogen.

13. The method of claim 12, wherein said amount of estrogen administered is not more than about 15 .mu.g per day.

14. The method of claim 12, wherein said amount of estrogen administered is between about 5 .mu.g and about 15 .mu.g per day.

15. A kit for use by a consumer afflicted with or susceptible to physical conditions resulting from postmenopausal estrogen decline, said kit comprising: a) a transdermal patch for transdermally administering an estrogen in an amount that is equivalent to less than about 15 .mu.g of estradiol per day; and b) instructions describing a method of using the transdermal patch to reduce the risk of osteoporotic bone fracture in said consumer.

16. A method for treating a physical condition resulting from estrogen decline in a postmenopausal subject, said method comprising administering transdermally an estrogen in an amount that is equivalent to less than about 20 .mu.g of estradiol per day to said subject, in the substantial absence of exogenous progestin, wherein serum level of said estrogen in said subject is equivalent to a serum estradiol level of between about 5 pg/ml and about 15 pg/ml, and wherein said physical condition is selected from the group consisting of osteoporosis, headaches, nausea, depression, hot flashes, decrease in bone mineral density, and increased risk or incidence of bone fracture.

17. The method of claim 16, wherein said physical conditions are selected from the group of postmenopausal estrogen decline, increased risk of osteoporotic bone fracture due to postmenopausal osteoporosis, and loss of bone mineral density.

18. The method of claim 16, wherein said administration is prior to hysterectomy of said subject.

19. The method of claim 16, wherein said estrogen is estradiol.

20. The method of claim 19, further comprising the step of testing the serum estradiol level of the subject and determining that the serum estradiol level of the subject to be treated is normal for postmenopausal women in the same age group as the subject.

21. The method of claim 19, wherein said amount of estrogen administered is between about 5 .mu.g and about 15 .mu.g per day.

22. The method of claim 19, wherein said amount of estrogen administered is about 10 .mu.g per day.

23. The method of claim 19, wherein said amount of estrogen administered is about 15 .mu.g per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc